---
title: Off-target toxicity
description: Predict off-target toxicity
---

[![path14](https://ai.ardigen.com/hubfs/Assets%20Oct%202022/path14.svg)](https://ai.ardigen.com/ardigen-immunology-offer?hsLang=en)

# Off-target toxicity

                 

### **Ardigen's ARDitox platform**

identifies cross-reactive epitopes, which are often impractical and expensive to find using traditional approaches (e.g. using X-scan).

Experimentally validated, patent pending (EP22461636).

[Main page](https://ai.ardigen.com/ardigen-immunology-offer?hsLang=en)

## Anticipate off-target toxicities in pHLA-targeting immunotherapies

### ARDitox for augmenting toxicity evaluation in pHLA-targeting immunotherapies

● Off-target toxicity can lead to side effects of variable intensity

● Intensity of the reactions depends on the type of tissues affected and the antigen expression level

● Our approach screens target epitopes assessing the risk of off-target toxicity

![Zrzut ekranu 2023-01-25 140825](https://ai.ardigen.com/hs-fs/hubfs/Zrzut%20ekranu%202023-01-25%20140825.png?width=666&height=579&name=Zrzut%20ekranu%202023-01-25%20140825.png "Zrzut ekranu 2023-01-25 140825")

### Main benefits

Identify therapeutic targets with the lowest risk of off-target toxicity events

Predict possible side-effects

 

Select which putative off-target epitopes should be tested experimentally

Design toxicity assays, based on the list of potentially affected tissues

## Choose targets with a low risk of side effects pinpointed by Ardigen's ARDitox platform

![Leaflet vaccine design_grafiki-07](https://ai.ardigen.com/hubfs/Leaflet%20vaccine%20design_grafiki-07.png "Leaflet vaccine design_grafiki-07")

Off-target toxicity

Identify potential off-target toxicities in cancer immunotherapies  
with Artificial intelligence to improve safety, and speed up therapy development

![Lleaflet target ID_grafiki-14](https://ai.ardigen.com/hubfs/Lleaflet%20target%20ID_grafiki-14.png "Lleaflet target ID_grafiki-14")

## **✓ Experimentally validated** (in collaboration with DKFZ)

ARDitox distinctive features

## ● Broader search: detects 2x more off-targets with a high risk of toxicity than the standard approach based on X-scan

## ● Holistic approach (see above) leveraging our ARDisplay-I model resulting in high accuracy of the method

## ● Insights into the TCR:pHLA interaction patterns by building on our TCRsuite platform

## Exemplary results

The MAGE-A3-specific T-cells infused to patients during a clinical trial did recognize not only the targeted epitope but also a Titin (TTN) peptide. The recognition of this peptide presented on healthy heart tissue has led to two fatalities.

With the ARDitox platform being tested retrospectively, we were able to anticipate the danger.

![Lleaflet target ID_grafiki-15](https://ai.ardigen.com/hubfs/Lleaflet%20target%20ID_grafiki-15.png "Lleaflet target ID_grafiki-15")

## ARDitox platform interactive dashboard

Provide target sequence and HLA type to obtain a list of putative off-targets, prioritized according to their safety score, along with the associated genes and their expression levels.

[Watch video](https://drive.google.com/file/d/1qspG2BZX3TdL9bHmnc1ufEKwkLFIm3_2/view?resourcekey)

![Screenshot from 2023-02-13 17-53-32](https://ai.ardigen.com/hubfs/Screenshot%20from%202023-02-13%2017-53-32.png "Screenshot from 2023-02-13 17-53-32")

# Are you interested in Ardigen's Immunology solutions?

![immunology_icon](https://ai.ardigen.com/hs-fs/hubfs/immunoikona.png?width=400&height=181&name=immunoikona.png)

### Immunity by design

Ardigen’s Immunology team specializes in tackling key challenges in immunotherapy development. To this end, we have developed cutting-edge technologies spanning multiple areas, including computational immunology, Artificial Intelligence, structural biology, and bioinformatics. This enables us to provide our clients with the most innovative solutions while streamlining therapy development.  
   
Whether you are working on TCR-Ts, TCRm-Abs, peptide-based vaccines, or other immunotherapy approaches, we would be excited to learn more about your projects and explore how we can support you.

### Do you have any questions?

[![path141](https://ai.ardigen.com/hubfs/Assets%20Oct%202022/path141.svg)](https://ardigen.com/)

- [![facebook](https://ai.ardigen.com/hubfs/Assets%20Oct%202022/facebook.svg)](https://www.facebook.com/Ardigen.SA)
- [![twitter](https://ai.ardigen.com/hubfs/Assets%20Oct%202022/twitter.svg)](https://twitter.com/Ardigen_SA)
- [![https://www.linkedin.com/company/ardigen-s-a-/](https://ai.ardigen.com/hubfs/Assets%20Oct%202022/link.svg)](https://www.linkedin.com/company/ardigen-s-a-/)